A rise in the number of incidences of Inborn Errors of Metabolism (IEM) and the preference for dietary supplements over Enzyme Replacement Therapy (ERT) are expected to drive the market growth. The lack of reimbursement facilities for these medical foods and also their high cost, potentially restraining the market growth.
